Meet Alfa Cytology at the Cancer R&D 2024, Nov 18-20, 2024. We look forward to connecting with you and providing expert solutions for your cancer drug development projects.

Learn More
In vivo PK for Cancer Therapy
Solutions
Online Inquiry

In vivo PK for Cancer Therapy

Pharmacokinetics (PK) plays a crucial role in defining the initiation, duration, and potency of drug effects within the body. Essential for the success of cancer therapy is the identification of candidates with favorable in vivo PK characteristics and the requirement for thorough preclinical assessments of efficacy and safety. At Alfa Cytology, we offer cutting-edge pharmacokinetic (PK) services tailored for cancer therapy research.

The Importance of In Vivo PK Studies

Schematic in vivo pharmacokinetics of immune checkpoint inhibitory drugs.Fig.1 Pharmacokinetics of ICIs. (Centanni, M., et al., 2019)

In the realm of oncology, in vivo pharmacokinetic (PK) studies serve as indispensable tools for refining tumor therapy strategies. Through these studies, researchers gain insights into the intricate dynamics of drug distribution, facilitating the optimization of dosage regimens tailored to target specific tumors.

For instance, ongoing PK investigations of emerging tumor drugs such as targeted therapies provide valuable data on their efficacy and potential interactions within the tumor microenvironment. Similarly, in the realm of immunotherapy, PK analyses of checkpoint inhibitors elucidate their impact on immune cell function and tumor infiltration, fostering the development of more potent and precise treatment modalities.

Our Services

In vivo PK for cancer therapy is a key aspect of drug development and its detailed understanding contributes to the successful application of cancer drugs. At Alfa Cytology, our dedicated scientists are committed to providing high-quality in vivo PK services for cancer research.

Blood Drug Concentration Measurement

Blood samples undergo High Performance Liquid Chromatography (HPLC) or Mass Spectrometry (MS) for drug concentration analysis, determining PK parameters.

Drug Metabolism and Excretion Pathway

Drug metabolism and excretion pathways are assessed by measuring drug and metabolite concentrations in urine and feces.

Drug Distribution in Tissues

Tissue sampling or PET scanning with radiolabeled drugs evaluates drug distribution in tumor and normal tissues.

Study of Drug Half-Life

Determining the half-life of the drug in the blood, usually by measuring the drug's plasma concentration at different time points.

Pharmacokinetic Study of Drug Metabolism

This includes identifying and quantifying the metabolic pathways of the drug in the body, as well as assessing the activity and toxicity of metabolites.

Drug Interactions

Assessing drug-drug interactions or drug transporter protein interactions influences the PK of the drug under study.

Available Models

Mouse

Rat

Rabbit

Beagle dog

Mini-pig

Monkey

Our Advantages

Optimizing Treatment Regimens

Understanding a drug's PK properties helps determine the optimal dose and timing to maximize efficacy and minimize side effects.

Guiding Drug Design and Optimization

PK properties are crucial for drug design and optimization, providing insights into absorption, distribution, metabolism, and excretion.

Predicting Drug Efficacy and Safety

PK characteristics influence drug concentration and duration in tissues, affecting efficacy and safety, allowing proactive adjustments.

Drug-Drug Interaction Studies

Understanding a drug's PK properties helps predict and manage drug-drug interactions in cancer patients, preventing adverse effects.

Our team at Alfa Cytology, equipped with advanced technology and diverse research models, ensures precise and comprehensive in vivo PK assay analysis. Collaborating closely with clients, we tailor projects to their research needs, contributing to cancer drug advancements. Feel free to contact us for our services.

Reference

  1. Centanni, M., et al.; (2019). Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clinical pharmacokinetics, 58, 835-857.

For research use only.